THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2018

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2018

WEBINARS

Register Now and
On Demand

Home » MARKETPLACE, Marketplace Archives

CMS extends coverage of Oncomine Dx test, 5/18

 

May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests. Combined with positive reimbursement decisions from commercial health insurers, the test is now available to more than 160 million people in the U.S.

The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Thermo Fisher Scientific, 866-356-0354

Print Friendly, PDF & Email
Tags:

X